Skip to content Skip to footer
Subscribe Now
Viewpoints_Mark Wildgust, Paolo Ghia & Paul Barr
VIEWPOINTS

PharmaShots Interview: Janssen’s Mark Wildgust along with Two Other Key Speakers Share Insights on Data Presented at ASCO 2021

In an interview with PharmaShots, Mark Wildgust, VP of Global Medical Affairs, Oncology at Janssen, Dr. Paolo Ghia, Division of Experimental Oncology at Università Vita-Salute San Raffaele and IRCCS Ospedale San Raffaele and Paul Barr, Associate Professor of Medicine and Director of the Clinical Trials Office for the Wilmot Cancer Institute at University of Rochester…
July 19, 2021

Read more

Viewpoints_Denis Corin
VIEWPOINTS

PharmaShots Interview: Q BioMed’s Denis Corin Shares Insights on the Agreement to Serve US Department of Defense and Veterans Affairs

In an interview with PharmaShots, Denis Corin, Chief Executive Officer and Chairman of the Board at Q BioMed share his views on the supply agreement for Strontium89 with the US Department of Defense and Veterans Affairs. Shots: BioMed has signed a 5-year agreement to commercially serve the US Department of Veterans Affairs (VA) and Department of Defense…
July 13, 2021

Read more

Viewpoints_Dr. Ramon Mohanlal
VIEWPOINTS

PharmaShots Interview: BeyondSpring’s Dr. Ramon Mohanlal Shares Insights on the Data of Triple Combo Plinabulin Presented at ASCO 2021

In an interview with PharmaShots, Ramon Mohanlal, M.D., Ph.D., MBA, Chief Medical Officer and Executive Vice President of Research and Development at BeyondSpring share his views on the data of triple combination regimen presented at ASCO and also shed light on the impact of plinabulin on SCLC. Shots: Plinabulin in combination with nivolumab and ipilimumab showed 46% ORR with one…
July 12, 2021

Read more

Viewpoints_Dr. Minnie Sarwal
VIEWPOINTS

PharmaShots Interview: NephroSant’s Dr. Minnie Sarwal Shares Insights on QSant and the Need for Precision Medicine in Kidney Health

In an interview with PharmaShots, Dr. Minnie Sarwal, CEO and Co-Founder of NephroSant shares her view on the QSant and how this urine test can improve outcomes for transplant patients. She also shed light on the need for precision therapies in kidney transplant care. Shots: NephroSant's Qsant is a needle-free urine test that helps in determining if…
July 7, 2021

Read more

Viewpoints_Juan Camilo Arjona Ferreira
VIEWPOINTS

PharmaShots Interview: Myovant’s Juan Camilo Arjona Ferreira Shares Insights on the Ryeqo

In an interview with PharmaShots, Myovant's Juan Camilo Arjona Ferreira, MD, Chief Medical Officer of Myovant Sciences shares his views on the CHMP's positive opinion for Ryeqo (Relugolix Combination Tablet). Shots: The CHMP has adopted positive opinion recommending approval of Ryeqo (relugolix 40 mg, estradiol 1.0 mg, and norethindrone acetate 0.5 mg) for the treatment of…
July 5, 2021

Read more

Viewpoints_Dr. Jan Wehkamp and Dr. Bruce Sands
VIEWPOINTS

PharmaShots Interview: Janssen’s Dr. Jan Wehkamp and Icahn School of Medicine’s Dr. Bruce Sands Share Insights on the Data Presented at DDW 2021

In an interview with PharmaShots, Dr. Jan Wehkamp, M.D., Vice President, Gastroenterology Disease Area Leader at Janssen, and Bruce Sands, Dr. Burrill B. Crohn Professor of Medicine at the Icahn School of Medicine share their views on the data of Stelara and Tremfya presented at DDW 2021. Shots: Janssen presented the new data on Stelara (ustekinumab) and…
July 2, 2021

Read more

Viewpoints_Andrea DiFabio
VIEWPOINTS

PharmaShots Interview: Repertoire’s Andrea DiFabio Shares Insights on the Importance of Series B Funding

In an interview with PharmaShots, Andrea DiFabio, JD, Chief Legal and Administration Officer of Repertoire Immune Medicines shares her views on the importance of $189M series B funding and how it will support the company's pipeline and manufacturing plans. Shots: The company reported the completion of a $189 million Series B financing. Founded by Flagship…
June 30, 2021

Read more

Insights+ Key Biosimilars Events of June 2021
INSIGHTS+

Insights+ Key Biosimilars Events of June 2021

Biosimilars are developed to be highly similar versions of approved biologics in terms of safety, purity, and potency Biosimilars are expected to be a cost-effective alternative to the high-priced branded biologics, offering significant and much-needed cost savings to both payers and the patients During the month of Jun, Celltrion launched Remsima SC (biosimilar, infliximab) for…
June 30, 2021

Read more

Load more